Treos Bio, a biotech using data science and proprietary biomarkers to develop precision peptide immunotherapies, has presented results from its Phase II OBERTO-301 study. A clinical-stage biotech ...

Generics giant Teva Pharmaceutical Industries and fellow Israel-based artificial intelligence (AI) focused biotech Biolojic Design have signed a license agreement to develop a potential novel antibody ...

The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, ...

While cancer-focused pharma and biotech are busy presenting their latest research achievements at the ongoing American Society of Clinical Oncology (ASCO) meeting, Germany’s Merck KGaA (MRK: DE) ...

With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight.

The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, ...

The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, ...

The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, ...

The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended eight novel drugs for approval at its May 2024 meeting.

Biotech firm Moderna (Nasdaq: MRNA) has won US Food and Drug Administration (FDA) approval for mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 ...

If approved, zolbetuximab would be the first CLDN18.2-targeted therapy available in the U.S. for these patients. The BLA was resubmitted following a complete response letter issued by the FDA on ...